The new facility, which is expected to be operational by mid-2026, will utilize cell-based technology to produce influenza vaccines for influenza pandemics and seasonal vaccination programs, both in Australia and globally.
Seqirus, a CSL company and an influenza vaccine provider based in the United States, announced on Nov. 16, 2020 that it will invest more than AUD $800 million (US$584 million) into building a new biotech manufacturing facility in Australia to supply influenza vaccines to Australia and globally.
The new facility, which is expected to be operational by mid-2026, will utilize cell-based technology to produce influenza vaccines for use in influenza pandemics and seasonal vaccination programs, a company press release said. Additionally, the facility will manufacture Seqirus’ proprietary adjuvant MF59, a substance added to vaccines to improve immune response and reduce the amount of antigen needed for each vaccine.
“Providing safe and effective influenza vaccines is essential in securing our defenses against serious public health threats,” said Paul Perreault, CSL’s CEO and managing director, in the press release. “The facility will be an important addition to our global influenza manufacturing supply chain, incorporating the technology platform used in our Holly Springs, North Carolina facility. Cell-based influenza vaccine technology offers many advantages over the existing process including being more scalable and offering faster production—particularly important in the case of influenza pandemics.”
Source: Seqirus
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.